First of more? Third Harmonic prices upsized IPO to raise $185M
Third Harmonic Bio pulled it off.
The Atlas-founded biotech, which came out of stealth just earlier this year with former Audentes CEO Natalie Holles at the helm, has priced an IPO that will bring in $185.3 million before taking commissions, discounts and other fees into account.
Given the chilly public market, it is perhaps unusual that Third Harmonic is making the jump to Nasdaq at all. Notably, while it priced in the middle of the proposed range — $17 per share — the company is boasting of an upsized offering. It ended up selling more than 10 million shares rather than the 9 million originally planned.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.